1. Scrip
  2. >>Therapy Areas

Array Rises On Binimetinib Data, 2016 Regulatory Submissions

 
• By Mandy Jackson

Array Biopharma gained 20.6% to close at $4.62 per share on Dec. 16 after the company said it will seek regulatory approvals for binimetinib based on results from the Phase III NEMO clinical trials, which showed the MEK inhibitor nearly doubled median progression-free survival (PFS) for NRAS-mutant melanoma patients to 2.8 months versus 1.5 months for dacarbazine (p

Array Biopharma gained 20.6% to close at $4.62 per share on Dec. 16 after the company said it will seek regulatory approvals for binimetinib based on results from the Phase III NEMO clinical trials, which showed the MEK inhibitor nearly doubled median progression-free survival (PFS) for NRAS-mutant melanoma patients to 2.8 months versus 1.5 months for dacarbazine (p<>

Binimetinib was a casualty of the massive asset swap between Novartis AG and GlaxoSmithKline PLC, in which Novartis acquired GSK's...

More from Anticancer

More from Therapy Areas

Viking Rapidly Advancing Oral And Injectable VK2735 For Obesity

 
• By Joseph Haas

In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By Kevin Grogan

The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.

Obesity Beyond GLP-1s: Amylins – The Next Frontier

 
• By Aakash Babu

In this series of articles, we look at different mechanisms of actions beyond GLP-1s that could determine the obesity drug landscape in the coming years. First on our list – amylin receptor agonists, which analysts expect to grow into a $50bn market opportunity.